Judge Tosses Ingenus Suit Over Leukemia Treatment Patent

By Editorial Team

A Delaware federal judge has agreed to throw out a lawsuit accusing Hetero Labs Ltd. of infringing a patent covering a treatment for lymphoma and leukemia, pointing out that an Illinois federal court in a separate case already found the patent to be invalid.

The lawsuit involved a patent numbered 10,993,952, which covers stable ready-to-use cyclophosphamide liquid formulations used in the treatment of leukemia and lymphoma. The decision to dismiss the case was made by the Delaware federal judge following a previous ruling in an Illinois federal court that deemed the patent invalid.

The legal battle included several law firms representing the parties involved. Morris James and Smith Katzenstein represented Hetero Labs Ltd., while Sughrue Mion and Wiley Rein represented the plaintiff, Ingenus Pharmaceuticals LLC.

Other companies involved in the case were Nexus Pharmaceuticals Inc. and government agencies such as the Food and Drug Administration. The case was heard in the U.S. District Court for the District of Delaware.

For more detailed information about the case, interested parties can refer to the court documents related to the lawsuit.